IL22 and atopic eczema: This suggests that during chronic inflammation conditions like GVHD, IL-22 may play a role that promotes disease progression rather than amelioration, fezakinumab treatment has been shown to improve clinical disease scores in patients with atopic dermatitis, particularly among those with elevated serum IL-22 levels [182].